Perspectum Diagnostics

Executive Summary

Perspectum Diagnostics is a UK-based medtech company leveraging advanced quantitative MRI to provide non-invasive biomarkers for liver, metabolic, and multi-organ diseases. Its proprietary technology extracts actionable imaging biomarkers, enabling earlier and more precise diagnosis, personalized treatment planning, and improved clinical outcomes. With a strong focus on metabolic-associated fatty liver disease (MAFLD) and non-alcoholic steatohepatitis (NASH), Perspectum addresses a significant unmet need by offering a radiation-free, reproducible alternative to invasive biopsies. The company has established collaborations with leading pharmaceutical firms for drug trial imaging endpoints, positioning itself as a key enabler in the growing precision hepatology market. Perspectum operates in a high-growth market driven by the global rise in obesity and diabetes, with the non-invasive liver diagnostics segment projected to exceed $3B by 2030. The company’s lead products, including LiverMultiScan and Iron-corrected T1, have gained CE marking and are used in over 40 clinical studies. Near-term focus includes expanding FDA clearances and securing commercial partnerships to drive adoption in the US and Asia. While facing competition from established alternatives like FibroScan, Perspectum’s multi-organ capability and deep-learning-enhanced imaging provide a differentiated value proposition. Continued validation through real-world evidence and regulatory milestones will be critical for market penetration and valuation growth.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for liver fat quantification in NAFLD/NASH70% success
• Q2 2027Strategic partnership with a top-10 pharmaceutical company for clinical trial imaging50% success
• Q3 2026Publication of pivotal study data on multi-organ MRI biomarkers80% success